Interferon Beta-1a — Membership Pricing

Other medications in Neurological

• Interferon Beta-1b
• Lacosamide
• Lasmiditan
• Meclizine
• Memantine
• Midazolam Nasal
• Natalizumab (Neurology)
• Nusinersen

About Interferon Beta-1a

Interferon beta-1a is a crucial medication used to manage certain forms of Multiple Sclerosis (MS), helping to reduce relapse frequency and slow disease progression. At TheDrugClub, we understand the financial burden of specialty medications. Our membership program is designed to help you access significant savings on vital prescriptions like interferon beta-1a, making your treatment more affordable.

What is Interferon Beta-1a and What Does It Treat?

Interferon beta-1a is an immunomodulator primarily prescribed for the treatment of relapsing forms of Multiple Sclerosis (MS). This includes Relapsing-Remitting MS (RRMS) and active Secondary Progressive MS (SPMS). MS is a chronic, autoimmune disease that affects the brain and spinal cord (the central nervous system). In MS, the body's immune system mistakenly attacks the protective sheath (myelin) that covers nerve fibers, leading to communication problems between the brain and the rest of the body. Interferon beta-1a works to reduce the frequency and severity of MS relapses and can slow the accumulation of physical disability.

How Does Interferon Beta-1a Work?

Interferon beta-1a is a synthetic version of a naturally occurring protein in the body called interferon. Interferons are part of the body's immune system, playing a role in regulating immune responses. In the context of MS, interferon beta-1a is believed to work by modulating the immune system. It helps reduce the inflammation and nerve damage associated with MS by decreasing the migration of inflammatory cells into the central nervous system and by promoting the production of beneficial anti-inflammatory compounds. This action helps to protect nerve cells and reduce the number of lesions that form in the brain and spinal cord, ultimately leading to fewer relapses and a slower progression of the disease. It is typically administered via subcutaneous or intramuscular injection.

Typical Costs of Interferon Beta-1a

As a specialty medication, interferon beta-1a can be quite expensive. Without insurance or significant discounts, the cost for a monthly supply can range from several thousand to over ten thousand dollars, depending on the specific brand, dosage, and pharmacy. These high costs can present a substantial barrier to treatment for many individuals. Factors influencing the final price include your insurance plan's formulary, deductible status, co-pay, and the pharmacy's pricing structure. It's important to remember that these are general estimates, and actual costs can vary widely.

How TheDrugClub Helps You Save

TheDrugClub is committed to helping our members afford their necessary medications. For interferon beta-1a, members may be able to access significant savings through our negotiated pricing. By presenting your TheDrugClub membership card at participating pharmacies, you can often receive substantial discounts off the retail price. While we cannot guarantee that this medication will be free or fully covered

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Interferon Beta-1a is approved for (FDA label)

AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AVONEX is for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: November 19, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Interferon Beta-1a (FDA label)

Injection: 30 micrograms per 0.5 mL clear, colorless solution in a single-dose prefilled syringe Injection: 30 micrograms per 0.5 mL clear, colorless solution in a single-dose prefilled autoinjector Injection: 30 micrograms per 0.5 mL solution in single-dose prefilled syringe ( 3 ) Injection: 30 micrograms per 0.5 mL solution in single-dose prefilled autoinjector ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d70a39cc-de15-4c12-a1ec-8063b69ea0e1. SPL document ID: 8c84155d-4436-404a-bb05-aee683889f0b. Label effective date: November 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Interferon Beta-1a (FDA label)

The following serious adverse reactions are discussed in more detail in other sections of labeling: Depression, Suicide, and Psychotic Disorders [see Warnings and Precautions ( 5.1 )] Hepatic Injury [see Warnings and Precautions ( 5.2 )] Anaphylaxis and Other Allergic-Reactions [see Warnings and Precautions ( 5.3 )] Injection Site Reactions Including Necrosis [see Warnings and Precautions ( 5.4 )] Congestive Heart Failure [see Warnings and Precautions ( 5.5 )] Decreased Peripheral Blood Counts [see Warnings and Precautions ( 5.6 )] Thrombotic Microangiopathy [see Warnings and Precautions ( 5.7 )] Pulmonary Arterial Hypertension [see Warnings and Precautions ( 5.8 )] Seizures [see Warnings and Precautions ( 5.9 )] Autoimmune Disorders [see Warnings and Precautions ( 5.10 )] Laboratory Tests [see Warnings and Precautions ( 5.11 )] The most common adverse reactions (at least 5% more frequent on AVONEX than on placebo) were flu-like symptoms including chills, fever, myalgia, and asthenia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Biogen at 1-800-456-2255 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of AVONEX cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: d70a39cc-de15-4c12-a1ec-8063b69ea0e1. SPL document ID: 8c84155d-4436-404a-bb05-aee683889f0b. Label effective date: November 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Interferon Beta-1a (FDA label)

AVONEX is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation [see Warnings and Precautions ( 5.3 )] . The formerly available lyophilized vial formulation of AVONEX is contraindicated in patients with a history of hypersensitivity to albumin (human). History of hypersensitivity to natural or recombinant interferon beta, albumin or any other component of the formulation ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: d70a39cc-de15-4c12-a1ec-8063b69ea0e1. SPL document ID: 8c84155d-4436-404a-bb05-aee683889f0b. Label effective date: November 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Interferon Beta-1a (FDA label)

Depression, Suicide, and Psychotic Disorders: advise patients to immediately report any symptoms of depression, suicidal ideation, and/or psychosis; consider discontinuation of AVONEX if depression occurs ( 5.1 ) Hepatic Injury: monitor liver function tests; monitor patients for signs and symptoms of hepatic injury; consider discontinuation of AVONEX if hepatic injury occurs ( 5.2 , 5.10 ) Injection Site Reactions: Do not administer AVONEX into affected area until fully healed; if multiple lesions occur, change injection site or discontinue AVONEX until healing of skin lesions ( 5.4 ). Anaphylaxis and Other Allergic-Reactions: Discontinue if occurs ( 5.4 ) Congestive Heart Failure: monitor patients with pre-existing significant cardiac disease for worsening of cardiac symptoms ( 5.5 ) Decreased Peripheral Blood Counts: monitor complete blood count ( 5.6 , 5.10 ) Thrombotic Microangiopathy: Cases of thrombotic microangiopathy have been reported.

Source: FDA prescribing information (DailyMed). Set ID: d70a39cc-de15-4c12-a1ec-8063b69ea0e1. SPL document ID: 8c84155d-4436-404a-bb05-aee683889f0b. Label effective date: November 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.